Kilitch Drugs (India) Ltd

KILITCH Stock View

(NSE)

168.10

263.73
Proj. ROE (%)
6.40
Proj. P/E (x)
-
Proj EV / EBITDA (x)
18.84
Proj. P/BV (x)
1.76
Proj. Revenue ( Cr.)
-

Stock View

STRONG BUY
Share on
The average score for Kilitch Drugs (India) Ltd stands at 6 against 4, three months back.

Kilitch Drugs (India) Limited is an India-based company, which is engaged in the development and operations of pharmaceutical business. It is primarily engaged in the development, manufacturing, and marketing of finished dosages. The Company’s products include parenteral solutions, effervescent, nutritional products, and medical device. Its products categories include urinary alkalizer, cephalosporins products, gastroenterology, non steroidal anti-inflammatory drugs (NSAIDs), anticonvulsant/antiepileptic, adrenergic agonist, neurotonic, muscle relaxant/stimulant, aminoglycosides, anti-infective, anti-inflammatory, anti-malarials, anti-hypertensive, anaesthetic, uterine stimulants. Its parenteral solutions include neurotonic, veterinary products, metered nasal drops, vaccines, oncology, and ophthalmic products. Its effervescent products include Roipar, Duregra, And Roivit. The Company offers nutritional products, such as Celtine. The Company also offers medical devices, such as C-Seal.

Disclaimer : All estimates (1 year forward) are based on Consensus View provided by Refinitiv.

Technical Data
50 DMA()
163.00
100 DMA ()
169.89
200 DMA ()
182.08
52 Weeks Range
145.00
275.10
Street View :-
Bearish
Open ZERO Brokerage Demat Account
Open Demat Account

  • 0

    Per Order for ETF & Mutual Funds Brokerage

  • 20

    Per Order for Delivery, Intraday, F&O, Currency & Commodity